Geron Corp. used a therapy made from stem cells taken from human embryos to treat a patient paralyzed by a spinal-cord injury in the first U.S.-authorized test of the controversial technology, according to Bloomberg. Geron's stock price rose a modest 6 percent to $5.67 on Monday.
Highlights of the important and the interesting from the world of healthcare: Zimmer comes under federal microscope: Often a thorn in the side of the device and drug industries, Iowa Sen. Charles Grassley is reprising the role–and this time the target is Zimmer Holdings. Grassley has asked Indiana-based Zimmer to disclose how it tracked the […]
How can AI benefit and improve patient outcome in the emergency department? Watch the latest episode to find out.
The stocks of stem cell therapy developers got a big boost on Tuesday, despite a huge loss for the overall stock market. Investors are expecting Pres. Barrack Obama to issue an executive order lifting a federal ban on funding research that uses embryonic stem cells.